PRESS RELEASE published on 09/18/2024 at 07:30, 1 year 9 months ago Half yearly financial reports and audit reports/limited reviews / Half yearly financial report Sensorion reports 2024 first half results including progress on SENS-501 and SENS-401 programs. Cash position strong at €87m. Future milestones and financial highlights outlined Sensorion Hearing Loss SENS-401 SENS-501 2024 Results
BRIEF published on 09/12/2024 at 07:35, 1 year 10 months ago Sensorion to Present at 59th Inner Ear Biology Workshop Conference Sensorion Hearing Loss Inner Ear Biology Proteomics
PRESS RELEASE published on 09/12/2024 at 07:30, 1 year 10 months ago Inside Information / Other news releases Sensorion announces participation in the 59th Annual Inner Ear Biology Workshop in Warsaw, Poland. Presentation on SENS-401 and gene therapy programs Gene Therapy Sensorion Hearing Loss SENS-401 Inner Ear Biology Workshop
BRIEF published on 09/02/2024 at 07:35, 1 year 10 months ago Sensorion at the World Congress of Audiology 2024 in Paris Gene Therapy Sensorion Hearing Loss World Congress Of Audiology Medical Symposium
PRESS RELEASE published on 09/02/2024 at 07:30, 1 year 10 months ago Inside Information / Other news releases Sensorion to lead symposium on medical advances in hearing loss at World Congress of Audiology in Paris, September 2024 Sensorion Hearing Loss Symposium World Congress Of Audiology Medical Advances
BRIEF published on 08/05/2024 at 07:35, 1 year 11 months ago Sensorion to Participate in Stifel's Biotech Summer Summit Investment Gene Therapy Sensorion Hearing Loss Biotech Summit 2024
PRESS RELEASE published on 08/05/2024 at 07:30, 1 year 11 months ago Inside Information / Other news releases Sensorion to participate in Stifel's Biotech Summer Summit 2024 to discuss strategic developments and gene therapy programs for hearing loss disorders Gene Therapy Sensorion Hearing Loss Disorders Stifel Biotech Summer Summit
BRIEF published on 06/27/2024 at 07:35, 2 years ago Sensorion Announces Appointment of New Chief Financial Officer Chief Financial Officer Biotechnology Sensorion Hearing Loss Laurene Danon
PRESS RELEASE published on 06/27/2024 at 07:30, 2 years ago Inside Information / Other news releases Sensorion appoints Laurene Danon as Chief Financial Officer, bringing 15 years of experience in investment banking. The company focuses on developing therapies for hearing loss disorders Chief Financial Officer Investment Banking Sensorion Laurene Danon Hearing Loss Therapies
BRIEF published on 05/30/2024 at 07:35, 2 years 1 month ago Sensorion announces the results of its Combined General Meeting Biotechnology Resolutions General Assembly Sensorion Hearing Therapies
Published on 07/13/2026 at 03:25, 1 hour 3 minutes ago SouthGobi Announces Inside Information JD Zhixing Fund L.P. Assigns Payment-In-Kind Interest Under Convertible Debenture
Published on 07/11/2026 at 02:50, 2 days 1 hour ago Alaska Energy Metals Reports on At-the-Market Equity Financing Program
Published on 07/11/2026 at 02:00, 2 days 2 hours ago Battery X Metals Presents Positive Preliminary Lithium-Ion Battery Rebalancing Trial Results Demonstrating Significant Estimated Driving Range Improvements and Accelerated Commercialization Progress of its Patent-Pending Lithium-Ion Battery Rebalancing Te
Published on 07/11/2026 at 02:00, 2 days 2 hours ago Discovery Energy Metals Announces Non-Brokered Private Placement Financing
Published on 07/11/2026 at 00:00, 2 days 4 hours ago Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010’s API
Published on 07/11/2026 at 04:00, 2 days ago CUHK Achieves Top 20 Global Ranking in QS World University Rankings 2027
Published on 07/10/2026 at 18:40, 2 days 9 hours ago AFX Surpasses $1.1 Billion in Total Trading Volume, Highlighting Capital Efficiency in On-Chain Derivatives
Published on 07/10/2026 at 17:45, 2 days 10 hours ago WYF Launches Global AI Talent Compact at AI for Good Global Summit 2026
Published on 07/10/2026 at 17:14, 2 days 11 hours ago Form 8.3 - SAFESTAY PLC: Opening Position Disclosure
Published on 07/10/2026 at 18:00, 2 days 10 hours ago Half-year liquidity contract statement for CEGEDIM
Published on 07/10/2026 at 10:34, 2 days 17 hours ago Number of shares and voting rights - June 2026 (In French only)
Published on 07/09/2026 at 18:00, 3 days 10 hours ago Second-quarter 2026 activity: +7% (vs. Q2 2025)
